Efficacy and Safety of Accelerated Intermittent Theta-burst Stimulation for Adolescents with Major Depressive Disorder: A Randomized, Double-Blind, Sham-controlled study.
{"title":"Efficacy and Safety of Accelerated Intermittent Theta-burst Stimulation for Adolescents with Major Depressive Disorder: A Randomized, Double-Blind, Sham-controlled study.","authors":"Xiaoli Liu, Ziyang Peng, Fang Cheng, Guangxue Li, Beini Wang, Changzhou Hu, Zhenzhen Zhu, Shasha Hu, Xinliang Luo, Jianzhou Sun, Shujun Wang, Jun Fu, Wenwu Zhang, Dongsheng Zhou","doi":"10.1016/j.biopsych.2025.07.018","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Developing safe and rapid treatments is crucial for adolescent major depressive disorder (MDD). While 10-session daily accelerated intermittent theta burst stimulation (a-iTBS) is effective in adults, its duration and safety limit its use in adolescents. This study evaluated a five-session daily a-iTBS protocol for adolescents with non-treatment-resistant MDD.</p><p><strong>Method: </strong>Seventy-four adolescents with non-treatment-resistant MDD were randomly assigned in a-iTBS or sham group. The a-iTBS group underwent five sessions of 1800-pulse iTBS per day targeting the left dorsolateral prefrontal cortex (DLPFC; Montreal Neurological Institute [MNI] coordinates: -44, 40, 29) using neuronavigation for ten consecutive days, while the sham group received intervention with a sham coil that provided haptic sensations and audible sounds. The 17-item Hamilton Depression Scale (HAMD-17), Hamilton Anxiety Scale (HAMA) and Children's Depression Inventory (CDI) were rated at baseline, the first day after the innervation (day 11), and the month 1 and 3 follow-up.</p><p><strong>Results: </strong>The a-iTBS group showed a significantly greater reduction in HAMD-17 compared with the sham group at day 11 (P < .001, Cohen'd = 0.86 [95% CI: 0.38, 1.33]) and month 1 follow-up (Cohen'd = 0.72 [95% CI: 0.24,1.18]). However, there was no statistically significant between the two groups at month 3 follow-up (P = .17, Cohen's d = 0.33 [95% CI: -0.13, 0.79]). The a-iTBS group showed significantly greater improvements in anxiety and self-reported depression at all time points compared to the sham group (all P-values < .05).</p><p><strong>Conclusion: </strong>A-iTBS is a safe and effective treatment for adolescents with non-treatment-resistant MDD, but the therapeutic effect diminished at the month 3 follow-up.</p><p><strong>Limitation: </strong>Although the study was blinded, clinician identification exceeded random chance in the a-iTBS group, suggesting that blinding may have been partially compromised.</p>","PeriodicalId":8918,"journal":{"name":"Biological Psychiatry","volume":" ","pages":""},"PeriodicalIF":9.0000,"publicationDate":"2025-07-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Biological Psychiatry","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.biopsych.2025.07.018","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"NEUROSCIENCES","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Developing safe and rapid treatments is crucial for adolescent major depressive disorder (MDD). While 10-session daily accelerated intermittent theta burst stimulation (a-iTBS) is effective in adults, its duration and safety limit its use in adolescents. This study evaluated a five-session daily a-iTBS protocol for adolescents with non-treatment-resistant MDD.
Method: Seventy-four adolescents with non-treatment-resistant MDD were randomly assigned in a-iTBS or sham group. The a-iTBS group underwent five sessions of 1800-pulse iTBS per day targeting the left dorsolateral prefrontal cortex (DLPFC; Montreal Neurological Institute [MNI] coordinates: -44, 40, 29) using neuronavigation for ten consecutive days, while the sham group received intervention with a sham coil that provided haptic sensations and audible sounds. The 17-item Hamilton Depression Scale (HAMD-17), Hamilton Anxiety Scale (HAMA) and Children's Depression Inventory (CDI) were rated at baseline, the first day after the innervation (day 11), and the month 1 and 3 follow-up.
Results: The a-iTBS group showed a significantly greater reduction in HAMD-17 compared with the sham group at day 11 (P < .001, Cohen'd = 0.86 [95% CI: 0.38, 1.33]) and month 1 follow-up (Cohen'd = 0.72 [95% CI: 0.24,1.18]). However, there was no statistically significant between the two groups at month 3 follow-up (P = .17, Cohen's d = 0.33 [95% CI: -0.13, 0.79]). The a-iTBS group showed significantly greater improvements in anxiety and self-reported depression at all time points compared to the sham group (all P-values < .05).
Conclusion: A-iTBS is a safe and effective treatment for adolescents with non-treatment-resistant MDD, but the therapeutic effect diminished at the month 3 follow-up.
Limitation: Although the study was blinded, clinician identification exceeded random chance in the a-iTBS group, suggesting that blinding may have been partially compromised.
期刊介绍:
Biological Psychiatry is an official journal of the Society of Biological Psychiatry and was established in 1969. It is the first journal in the Biological Psychiatry family, which also includes Biological Psychiatry: Cognitive Neuroscience and Neuroimaging and Biological Psychiatry: Global Open Science. The Society's main goal is to promote excellence in scientific research and education in the fields related to the nature, causes, mechanisms, and treatments of disorders pertaining to thought, emotion, and behavior. To fulfill this mission, Biological Psychiatry publishes peer-reviewed, rapid-publication articles that present new findings from original basic, translational, and clinical mechanistic research, ultimately advancing our understanding of psychiatric disorders and their treatment. The journal also encourages the submission of reviews and commentaries on current research and topics of interest.